AKiyoshi, MD, PhD

Physician, Cardiology 🫀

[カレーの店 マボロシ @CSMaboroshi]

明日13(日)19:00〜Fm yokohama 84.7

“アレキとか！ドロスとか！”

呼んでいただきました❗️レトルトの話もすこし😆よろしくお願いしますー

#アレドロ
#Alexandros
#カレー
#レトルトカレー

https://t.co/Q5CfRsI54z

[AKiyoshi, MD, PhD @akiyoshiMD]

【大喜利】母校の入試面接、その一言で合格決定！？

https://t.co/VNZpMWAfDU

[AKiyoshi, MD, PhD @akiyoshiMD]

#AHA23 @AHAScience

[国境なき医師団 @MSFJapan]

【📢 オンライン署名にご協力を】
イスラエルとパレスチナでの衝突の激化により多くの命が失われています。

国境なき医師団は紛争当事者に対し
✅無差別攻撃の即時停止
✅医療の保護
✅人道性の回復
を求めオンライン署名を行っています。

👇署名はChange. orgのサイトから
https://t.co/JCuZzZHaMW

[NEJM @NEJM]

Results of OCTOBER trial presented at #ESCCongress:

In patients with coronary bifurcation lesions, PCI with optical coherence tomography guidance was associated with a lower incidence of major adverse cardiac events at a median of 2 years than angiography-guided PCI.

[Cardiology Now News @CardioNowNews]

STOPDAPT-3: Prasugrel monotherapy after PCI with DES not superior to DAPT for major bleeding but non-inferior for CV events

Written by @adam_dr_ !

Summary and analysis and more #ESCCongress coverage below! https://t.co/7Rw0TR6P2m

@CMichaelGibson

[Bartosz Hudzik MD PhD FESC FACC @BartoszHudzik]

#antiplatelet management of #ACS 👉#ESCCongress @escardio @ESC_Lavinia @mmamas1973 @DFCapodanno @vlgmrc @Drroxmehran @gbiondizoccai @FeliceGragnano @DrMarthaGulati @biljana_parapid @DocSavageTJU @DavidLBrownMD @mirvatalasnag @SABOURETCardio @Hragy @ErinMichos @VijayKunadian

[Joy Ong @JoyYSOng]

📢 Happening now in Sophia: Role of AI in Intravascular imaging by Dr Jason Chen - to look towards being #predictive and #prescriptive, rather than just descriptive 🦾 #NUHCS #AI #APSC2023Singapore @APSC2023

[AKiyoshi, MD, PhD @akiyoshiMD]

#APSC2023Singapore 🇸🇬

[AKiyoshi, MD, PhD @akiyoshiMD]

#ESCCongress

[European Society of Cardiology @escardio]

#REVIVED trial: Percutaneous coronary intervention does not reduce all-cause mortality or #heartfailure hospitalisation in patients with severe left ventricular dysfunction and extensive #coronary artery disease.

#ESCCongress

[AKiyoshi, MD, PhD @akiyoshiMD]

#ESCCongress

[European Society of Cardiology @escardio]

#DELIVER trial: dapagliflozin reduces the risk of #cardiovascular death or worsening #heartfailure in HF patients with mildly reduced and preserved ejection fraction.

#ESCCongress

[AKiyoshi, MD, PhD @akiyoshiMD]

Employment status and its associated factors for patients 12 months after intensive care: Secondary analysis of the SMAP-HoPe study
https://t.co/i64NOAiBB3
@TakeshiUnoki

🏥ICU ➡️ 24.1%🥷🙅

[AKiyoshi, MD, PhD @akiyoshiMD]

Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease
https://t.co/uNdFWKB2AO

[AKiyoshi, MD, PhD @akiyoshiMD]

#HFpEF 👀
Recommendations for Patients With Preserved LVEF (≥50%)

https://t.co/2WV69G813l
#ACC22

[AKiyoshi, MD, PhD @akiyoshiMD]

《2022 AHA/ACC/HFSA Guideline for
the Management of Heart Failure》

✅Classification and Trajectories of HF Based on LVEF
https://t.co/NWIUcXGSG0
#ACC22

[AKiyoshi, MD, PhD @akiyoshiMD]

セラピードッグとの触れ合いが救急患者の痛みや不安を軽減
https://t.co/g8Ox1gbNoR

[AKiyoshi, MD, PhD @akiyoshiMD]

@long @BoredApeYC @LazyLionsNFT @WickedCraniums @MarsCatsVoyage gm!!

[AKiyoshi, MD, PhD @akiyoshiMD]

@STR0 @elash24 gm🦁 #LazyLions

[AKiyoshi, MD, PhD @akiyoshiMD]

@BrittanyBowe congrats!! #LazyLions🦁